Safety, Clinical Activity, Pharmacokinetics (PK) and Pharmacodynamics Study of GSK2879552, Alone or With Azacitidine, in Subjects With High Risk Myelodysplastic Syndromes (MDS)
Stopped The risk benefit in the study population does not favor continuation of the study
Conditions
- Myelodysplastic Syndrome
- Myelodysplastic Syndromes
Interventions
- DRUG: GSK2879552
- DRUG: Azacitidine
Sponsor
GlaxoSmithKline
Collaborators